Serologic test for neonatal hemochromatosis in infants with acute liver failure

急性肝功能衰竭婴儿新生儿血色素沉着症的血清学检测

• 批准号: 7943986
• 负责人: PETER Frank WHITINGTON
• 金额: $ 28.1万
• 依托单位: LURIE CHILDREN'S HOSPITAL OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7943986
• 关键词: Acute Liver Failure; Address; Affect; Age; Antibodies; Area; Binding; Biological Assay; Biological Markers; Child; Childhood; Clinical; Clinical Research; Collaborations; Collection; Complement; Complement Membrane Attack Complex; Diagnosis; Diagnostic; Etiology; Fetal Liver; Funding; Goals; Gold; Hemochromatosis; Hepatic; Hepatocyte; Histopathology; Immunofluorescence Immunologic; Immunoglobulin G; Infant; Infant Mortality; Injury; Investigation; Knowledge; Lead; Life; Liver; Liver Failure; Liver diseases; Mediating; Medical; Methods; Morbidity - disease rate; Mothers; Neonatal; Outcome; Patients; Population; Population Study; Prevalence; Qualifying; Research; Sampling; Sensitivity and Specificity; Series; Serologic tests; Serum; Siderosis; Staging; Testing; Validation; Woman; Work; age group; conventional therapy; diagnostic accuracy; fetal; improved; innovation; isoimmunity; liver transplantation; maternal serum; mortality; neonatal morbidity; neonate; novel; novel diagnostics; public health relevance; repository; tool

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (04) Clinical Research and specific Challenge 04-DK-104 Improve the diagnosis, staging and treatment of diseases of the liver. This application specifically seeks to develop an approach that will improve the diagnosis of acute liver failure in infants, result in significantly improved outcome with medical therapy, and reduce the utilization of liver transplantation in pediatric patients. Neonatal hemochromatosis (NH) is the leading diagnosed cause of liver failure in neonates in most series. However, no diagnosis for acute liver failure can be established in up to 40% of infants. The overall objective of this application is to determine the true prevalence of NH as a cause of acute liver failure in infants d 90 days of age. The critical gap in scientific knowledge to be overcome before its importance as cause of acute liver failure can be determined is the lack of a sensitive and specific diagnostic biomarker for NH. Since NH is caused by maternal alloimmunity against fetal liver, the biomarker proposed is the presence of "anti-fetal hepatocyte IgG antibody" in mothers' or infants' serum. The diagnostic utility of an immunofluorescence assay for this biomarker is to be established and then it will be used to assess the prevalence of NH in a population of young infants with acute liver failure. Normally acquiring a study population large enough to power such a study would require many years of study. However, sera obtained from the Pediatric Acute Liver Failure study repository will be used, making it feasible to complete the proposed work within the timeframe of two years. The expected results will show that NH constitutes fully 50% of all causes of acute liver failure in young infants. This finding will have a significant positive impact because NH is responsive to specific medical therapy, which improves outcome over current treatment including liver transplantation. Furthermore, should the novel test used in this analysis prove to be sensitive and specific for the diagnosis, it could replace current diagnostic approaches and prospectively improve diagnostic accuracy in this setting. Thus, early, precise diagnosis could lead to improved outcome and reduced utilization of liver transplantation. PUBLIC HEALTH RELEVANCE: Neonatal Hemochromatosis (NH) is an important cause of liver failure in infants, but the diagnosis may be easily missed. A novel serological test will be used to determine if NH is the cause of the nearly 40% of pediatric acute liver failure without diagnosis. Since NH is responsive to medical treatment, improving the diagnosis of acute liver failure could save the lives of many infants and substantially reduce the need for liver transplantation in children.

描述（由申请人提供）：该申请涉及广泛的挑战领域（04）临床研究和特定的挑战04- dk -104改善肝脏疾病的诊断、分期和治疗。本应用程序旨在开发一种方法，以提高婴儿急性肝衰竭的诊断，显著改善药物治疗的结果，并减少儿科患者肝移植的使用。新生儿血色素沉着症（NH）是大多数系列新生儿肝衰竭的主要诊断原因。然而，高达40%的婴儿无法确诊急性肝衰竭。本应用程序的总体目标是确定NH作为90日龄婴儿急性肝衰竭原因的真实患病率。在确定其作为急性肝衰竭原因的重要性之前，需要克服的关键科学知识差距是缺乏对NH敏感和特异性的诊断生物标志物。由于NH是由母体对胎儿肝脏的同种免疫引起的，因此提出的生物标志物是母亲或婴儿血清中存在“抗胎儿肝细胞IgG抗体”。该生物标志物的免疫荧光检测的诊断效用将被建立，然后它将被用于评估新生儿急性肝衰竭人群中NH的患病率。通常情况下，获得足够大的研究人群来进行这样的研究需要多年的研究。然而，将使用从儿童急性肝衰竭研究库获得的血清，这使得在两年的时间框架内完成拟议的工作成为可能。预期的结果将表明，NH占婴儿急性肝衰竭所有原因的50%。这一发现将产生重大的积极影响，因为NH对特定的药物治疗有反应，这比目前的治疗（包括肝移植）改善了结果。此外，如果在本分析中使用的新测试被证明对诊断是敏感和特异性的，它可以取代目前的诊断方法，并有望提高这种情况下的诊断准确性。因此，早期、准确的诊断可以改善预后，减少肝移植的使用。